Krystal Biotech, Inc. (KRYS)
NASDAQ: KRYS · IEX Real-Time Price · USD
159.67
+6.55 (4.28%)
At close: May 1, 2024, 4:00 PM
159.00
-0.67 (-0.42%)
After-hours: May 1, 2024, 4:49 PM EDT
Krystal Biotech Revenue
In the year 2023, Krystal Biotech had annual revenue of $50.70M. Revenue in the quarter ending December 31, 2023 was $42.14M.
Revenue (ttm)
$50.70M
Revenue Growth
n/a
P/S Ratio
89.10
Revenue / Employee
$221,393
Employees
229
Market Cap
4.52B USD
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 50.70M | - | - |
| Dec 31, 2022 | 0 | - | - |
| Dec 31, 2021 | 0 | - | - |
| Dec 31, 2020 | 0 | - | - |
| Dec 31, 2019 | 0 | - | - |
| Dec 31, 2018 | 0 | - | - |
| Dec 31, 2017 | 0 | - | - |
| Dec 31, 2016 | 0 | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Perrigo Company | 4.66B |
| Alkermes | 1.66B |
| Lantheus Holdings | 1.30B |
| Merit Medical Systems | 1.26B |
| Doximity | 468.33M |
| CRISPR Therapeutics AG | 371.21M |
| Alpine Immune Sciences | 58.88M |
KRYS News
- 5 days ago - Krystal Biotech to Report First Quarter 2024 Financial Results on May 6, 2024 - GlobeNewsWire
- 9 days ago - Krystal Biotech Announces First Patient Dosed in Phase 1 Clinical Trial of Inhaled KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors of the Lung - GlobeNewsWire
- 27 days ago - Krystal Biotech to Present at the American Association for Cancer Research 2024 Annual Meeting - GlobeNewsWire
- 2 months ago - Krystal Biotech to Present at TD Cowen 44th Annual Health Care Conference - GlobeNewsWire
- 2 months ago - Krystal Biotech Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updates - GlobeNewsWire
- 2 months ago - Krystal Biotech to Report Fourth Quarter and Full Year 2023 Financial Results on February 26, 2024 - GlobeNewsWire
- 2 months ago - Krystal Biotech Receives FDA Fast Track Designation for Inhaled Oncology Candidate KB707 to Treat Solid Tumors of the Lung - GlobeNewsWire
- 2 months ago - Krystal Biotech Announces Publication in the New England Journal of Medicine on the Application of B-VEC to Treat Ocular Complications in Patient with Dystrophic Epidermolysis Bullosa - GlobeNewsWire